Tag Archives: Invest

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

21 Jun

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: West Coast-Based Family Office Invests Up to $10M Into Early-Stage Therapeutics, Devices, and Tools Companies

31 May

A family office based in the West Coast invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: USA Venture Fund Invests in Therapeutics and Digital Health, With Strong Interests in Small Molecule Therapies in Inflammation, Infectious, Autoimmune Diseases

31 May

A USA-based venture capital fund is currently making investments out of a $150-million-dollar fund. The firm is looking to make 15 additional investments with allocations generally in the $1-3 million range. The firm is looking to make equity investments and is open to investing in companies globally.

The firm is interested in therapeutic companies developing small molecules for inflammation, infectious and autoimmune disease and stays away from biologics, cell and gene therapy. The firm is also interested in digital health and mobile health services, AI in healthcare, B2B2C medical devices. The firm is looking for companies with some level of proof-of-concept data either in vivo or in vitro up until Phase II of clinical trials. As for digital health, the firm is looking for scalable SAAS models, novel types of healthcare delivery, point-of-care diagnostics and patient’s self-management tools.

The firm is willing to work with incomplete management teams, often working with IP that has just recently spun out of a university. The firm is willing and able to act as a lead or co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: